FIELD: biotechnologies.
SUBSTANCE: peptide is characterised with sequence Lys-Leu-Lys-Gln-Lys-Leu-Ala-Glu-Leu-Leu-Glu-Asn-Leu-Leu-Glu-Arg-Phe-Leu-Asp-Leu-Val-Inp (SEQ ID NO: 16). The invention also relates to peptide/lipid complex based on the above peptide, in which phospholipid represents one or more of sphingomyelin, DPPC and DPPG, a pharmaceutical composition that contains it, and treatment methods of dyslipidemia, cardiovascular disease, endothelial malfunction, macrovascular illnesses and microvascular illnesses using it.
EFFECT: invention allows obtaining ApoA-I mimetic that is more stable in comparison to ApoA-I and that is easy to obtain.
14 cl, 21 dwg, 14 tbl, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
| ANALOGUES OF EGF(A) WITH SUBSTITUENTS-FATTY ACIDS | 2017 |
|
RU2747877C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| METHODS FOR TREATMENT OF HYPERLIPIDEMIA IN PATIENTS WITH DIABETES BY INJECTION OF PCSK9 INHIBITOR | 2018 |
|
RU2772712C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| NEW ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION | 2018 |
|
RU2805674C2 |
